Bioclonetics | Startup Investing | Stratifund
 

Bioclonetics
Biotechnology

Stratifund Rating:

Summary

Location: 
Texas
Deal Type: 
Title III Future Equity (SAFE)
Deal Status: 
Funding
Target Offering Amount: 
Min: $200,000
Max: $1,000,000
Minimum Investment Required: 
Min: $100

Get the full unbiased report

Subscribe for access

BioClonetics is finalizing the production and testing of a monoclonal antibody to treat patients with HIV.